阿托伐他汀联合低分子肝素治疗COPD急性加重期疗效观察

摘要

Objective To investigate the clinical effect of atorvastatin combined with low molecular heparin in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods A total of 50 patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into observation group and control group, with 25 cases in each group. The control group received conventional treatment, and the observation group received additional combined treatment by atorvastatin and low molecular. Curative effects were evaluated. Results There were statistically significant differences of arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen (PaO2), oxyhemoglobin saturation, and prothrombin time between the observation group and control group (P<0.05). The observation group had higher total effective rate after treatment as 96.0% than 68.0% of the control group, and the difference had statistical significance (P<0.05). Conclusion Combination of atorvastatin and low molecular provides remarkable effect in treating acute exacerbation of chronic obstructive pulmonary disease, and this method is worthy of reference.%目的：探讨阿托伐他汀联合低分子肝素治疗慢性阻塞性肺疾病(COPD)急性加重期的临床效果。方法50例慢性阻塞性肺疾病急性加重期患者，随机分为观察组和对照组，每组25例。对照组采用常规治疗，观察组在常规治疗的基础上给予低分子肝素和阿托伐他汀联合治疗。评定治疗效果。结果观察组治疗后的动脉血二氧化碳分压(PaCO2)、动脉血氧分压(PaO2)、血氧饱和度及凝血酶原时间和对照组比较，差异有统计学意义(P<0.05)。观察组治疗后的总有效率96.0%高于对照组68.0%，差异有统计学意义(P<0.05)。结论阿托伐他汀联合低分子肝素治疗慢性阻塞性肺疾病急性加重期疗效显著，值得借鉴。